Smyth.

Methods	Multicentre randomised controlled trial. Generation of allocation schedule truly random.
Participants	190 patients with recurrent or metastatic colorectal cancer not amenable to curative surgery and/or radiotherapy. WHO performance status 0‐2, life expectancy at least 3 months. Specified levels of haematological and hepatic function required. Excluded if previous chemotherapy or radiotherapy to lesions. Patients with concomitant malignant disease were excluded. Excluded if active uncontrolled infection or poor medical risks because of non‐malignant systemic disease.
Interventions	Tauromustine (130mg/m2 p.o. every 5 weeks). Continued until evidence of disease progression vs No chemotherapy Radiotherapy was permitted for palliative treatment. Other cytotoxic agents were not permitted.
Outcomes	Survival, Progression, Tumour response, Quality of life, Performance status, Toxicity
Notes	Only published as a short communication. Additional information supplied by Kabi Pharmacia. Analysis was by intention to treat.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate